Quick Answer
Ultragenyx Pharmaceutical Inc. reported Net Income Loss of -$575.00 million for the year ending 2025.
- Ultragenyx Pharmaceutical Inc. showed a decrease of -1.1% in Net Income Loss from 2024 to 2025.
- This data is from Ultragenyx Pharmaceutical Inc.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Ultragenyx Pharmaceutical Inc.'s Net Income Loss has declined by 3,420.3%.
- Historical annual values: Fiscal year 2025: -$575.00 million | Fiscal year 2024: -$569.00 million | Fiscal year 2023: -$607.00 million | Fiscal year 2022: -$707.42 million | Fiscal year 2021: -$454.03 million | Fiscal year 2020: -$186.57 million | Fiscal year 2019: -$402.73 million | Fiscal year 2018: -$197.61 million | Fiscal year 2017: -$302.14 million | Fiscal year 2016: -$245.87 million | Fiscal year 2015: -$145.62 million | Fiscal year 2014: -$59.80 million | Fiscal year 2013: -$35.07 million | Fiscal year 2012: -$16.33 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: